CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,010 enrolled
Drug / intervention
polymixin/bacitracin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02809131
NCT02809131Phase 3Completed

Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients

Vanderbilt University Medical Center·interventional·Posted Jun 22, 2016·Updated May 9, 2022

In Brief

A Phase 3 clinical trial evaluating polymixin/bacitracin, cephalexin, or levofloxacin, or clindamycin, and 1 other intervention for Sick Sinus Syndrome and 3 related conditions. Completed, enrolled 1,010 participants across 1 site.

Detailed Summary

The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or intravascular leads, have become increasingly prevalent, with the rate of growth in infections outpacing that of CIED procedures. The odds of both short term and long term mortality are at least doubled in patients who suffer CIED infections, and long term survival is particularly poor in women. Optimal strategies to prevent CIED infections in high-risk patients are largely unproven. However, recent observational studies of an antibiotic-coated envelope implanted at the time of CIED procedure have shown that this strategy is associated with a low incidence of CIED infections. Other interventions to prevent CIED infections, including the use of antibiotic irrigant used to wash the pocket during implantation and postoperative oral antibiotics, are commonly used but not supported by rigorous controlled studies. The Specific Aim of this study is to test the hypothesis that the use of the antibacterial envelope alone is noninferior to a strategy using the antibacterial envelope and intraoperative antibacterial irrigant and postoperative oral antibiotics for the reduction of cardiac implantable device infections in patients with ≥2 risk factors for infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 22, 2016
Enrollment StartApr 1, 2016
Primary CompletionMar 31, 2021
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 10.0 years ago

Interventions

polymixin/bacitracindrug

Antibacterial irrigation

cephalexin, or levofloxacin, or clindamycindrug

Post operative oral antibiotics

Salinedrug

Saline irrigation